Joel Ackerman - CEO

Good morning. I'm Joel Ackerman, the CEO of Champions Oncology. Thank you for joining us for our quarterly earnings call. I'll start the call today with highlights and updates since our last call, discuss the financial results, and then open up the call for questions. Before I start, I will remind you that I'll make forward-looking statements during the call and actual results could differ materially from what is described in those statements. Additional information on factors that could cause results to differ is available in our Forms 10-Q and 10-K. Reconciliation of non-GAAP financial measures that may be discussed on the call to GAAP financial measures is available in the earnings release. To start, I'm going to focus on recent highlights, which accentuate our continuing strategy to develop new areas of growth that facilitates the development of proprietary uses of our TumorGraft platform. The first highlight that I'd like to talk about is a new product we're developing that we call ImmunoGrafts. This product involves implanting our TumorGraft models in severely immune compromised mice that have had a human immune system implanted in them. This combination of a human immune system and the TumorGraft both implanted in a mouse allows for the testing of a new class of immune modulating drugs. As background, Immune Oncology is clearly the hottest new area in oncology drug development. The successive of new compounds in achieving durable responses in patients has created a buzz around immune oncology that is hard to avoid because TumorGrafts are typically implanted in mice that are immune compromised the mechanism of immune therapies namely recruiting the immune system to attack the cancer cannot work. So to overcome this problem. We've started to use humanized mice namely mice with human immune systems implanted within them. A combination of human…

Great. Well thank you all for joining us today. We look forward to keeping you updated in the future. Have a good day.

That concludes this morning's teleconference. You may now disconnect your line.